Scripps Research Logo

News Release

TSRI Scientists Show How Drug Binds with ‘Hidden Pocket’ on Flu Virus

New Study Reveals Precisely How Popular Flu Treatment Arbidol Works

LA JOLLA, CA – December 21, 2016 – A new study led by scientists at The Scripps Research Institute (TSRI) is the first to show exactly how the drug Arbidol stops influenza infections. The research reveals that Arbidol stops the virus from entering host cells by binding within a recessed pocket on the virus.

The researchers believe this new structural insight could guide the development of future broad-spectrum therapeutics that would be even more potent against influenza virus.

“This is a very interesting molecule, and now we know where it binds and precisely how it works,” said study senior author Ian Wilson, Hansen Professor of Structural Biology, chair of the Department of Integrative Structural and Computational Biology and member of the Skaggs Institute for Chemical Biology at TSRI.

The study was published today in the journal Proceedings of the National Academy of Sciences.

Treatment Can Target Many Strains of Influenza

Arbidol (also called umifenovir) is an anti-flu treatment sold in Russia and China by the Russian pharmaceutical company Pharmstandard. The drug is currently in stage-four clinical trials in the United States.

The drug targets many strains of influenza, giving it an advantage over seasonal vaccines that target only a handful of strains. The new study sheds light on exactly how it accomplishes this feat.

Scientists had long been curious whether Arbidol bound to the viral proteins used to recognize host cells—or with the viral “fusion machinery” that enters and infects host cells. To answer this question, the researchers used a high-resolution imaging technique called X-ray crystallography to create 3D structures showing how Arbidol binds to two different strains of influenza virus.

The structures revealed that Arbidol binds to the virus’s fusion machinery, as some had suspected. The small molecule binds to a viral protein called hemagglutinin, stopping the virus from rearranging its conformation in a way that enables the virus to fuse its membrane with a host cell.

“We found that the small molecule binds to a hidden pocket in hemagglutinin,” said study first author Rameshwar U. Kadam, senior research associate at TSRI. He added that the drug acts as a sort of “glue” to hold the subunits of hemagglutinin together. “Arbidol is the first influenza treatment shown to use a hemagglutinin-binding approach,” he said.

This vulnerable pocket is “conserved,” meaning it is likely important for viral function—and more difficult to mutate as the virus spreads—suggesting why Arbidol has relatively broad use in fighting many strains of the virus, including emerging strains.

The new findings also help scientists understand how Arbidol compares to influenza treatments such as Tamiflu. Wilson explained that Tamiflu prevents the virus from getting out of cells, while Arbidol prevents it from getting in. This means Arbidol, or future drugs that take a similar approach, could be given as a preventative treatment before an outbreak hits.

“When we had the 2009 H1N1 pandemic, the vaccine came too late,” said Wilson. “If we had a front-line therapeutic, that could have worked much better until a vaccine was ready.”

Wilson said the next step for researchers is to discover and/or design other small molecule therapeutics that can bind even more tightly with the hemagglutinin.

This study, “Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol,” was supported by the National Institutes of Health (grant R56 AI117675) and an Early Mobility Postdoctoral Fellowship from the Swiss National Science Foundation. This study used resources funded in whole or in part by the National Cancer Institute (grant Y1-CO-1020); the National Institute of General Medical Science (grant Y1-GM-1104); the U.S. Department of Energy, Basic Energy Sciences, Office of Science (contracts DE-AC02-06CH11357 and DE-AC02-76SF00515); the U.S. Department of Energy, Office of Biological and Environmental Research and by the National Institute of General Medical Science (grant P41GM103393).

About The Scripps Research Institute

The Scripps Research Institute (TSRI) is one of the world's largest independent, not-for-profit organizations focusing on research in the biomedical sciences. TSRI is internationally recognized for its contributions to science and health, including its role in laying the foundation for new treatments for cancer, rheumatoid arthritis, hemophilia, and other diseases. An institution that evolved from the Scripps Metabolic Clinic founded by philanthropist Ellen Browning Scripps in 1924, the institute now employs more than 2,500 people on its campuses in La Jolla, CA, and Jupiter, FL, where its renowned scientists—including two Nobel laureates and 20 members of the National Academies of Sciences, Engineering or Medicine—work toward their next discoveries. The institute's graduate program, which awards PhD degrees in biology and chemistry, ranks among the top ten of its kind in the nation. For more information, see www.scripps.edu.

# # #

For information:
Office of Communications
Tel: 858-784-2666
Fax: 858-784-8118
press@scripps.edu


Professor Ian Wilson (left) and Senior Research Associate Rameshwar U. Kadam led the study at The Scripps Research Institute. (Photo by Madeline McCurry-Schmidt.) (High-res image)


FOR MORE INFORMATION